Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PPP5C | P53041 | 1/20 | 0.34 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638214 | 0.92 | TSHR (0.46) | TSHRKDM4EGMNNPPM1BLMNA | |
| SCHEMBL14125402 | 0.85 | TSHR (0.50) | TSHRKDM4EGMNNPPM1BLMNA | |
| SCHEMBL9718442 | 0.85 | TSHR (0.50) | TSHR | |
| SCHEMBL5495656 | 0.85 | — | — | |
| SCHEMBL496859 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL10636423 | 0.83 | TSHR (0.39) | TSHRKDM4EGMNNPPM1BLMNA | |
| SCHEMBL238394 | 0.80 | — | — | |
| SCHEMBL1484120 | 0.80 | — | — | |
| SCHEMBL8060861 | 0.80 | — | — | |
| SCHEMBL5165814 | 0.78 | TSHR (0.37) | TSHRCA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999032887-A1 | DETECTION OF PROSTATE DISEASE BY MEASURING NAALADASE ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-01 | — | — | WO | claimed |
| EP-4676472-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| CN-119367415-A | Application of MLCT in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease | 浙江科技大学 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024191886-A9 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | PURDUE RESEARCH FOUNDATION (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240307423-A1 | FRACTIONS OF, AND MOLECULES RELEASED IN, PROTEIN RICH PLASMA WHICH INHIBIT IMMUNE RESPONSES AND REDUCE INFLAMMATION, AND METHODS OF OBTAINING | New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special S (US) | 2024-09-19 | — | — | US | disclosed |
| WO-2024191886-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF TUMORS AND THE INHIBITION OF CANCER-ASSOCIATED FIBROBLASTS | PURDUE RESEARCH FOUNDATION (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2022173935-A1 | FRACTIONS OF, AND MOLECULES RELEASED IN, PROTEIN RICH PLASMA WHICH INHIBIT IMMUNE RESPONSES AND REDUCE INFLAMMATION, METHODS OF USE AND METHODS OF OBTAINING | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-105636924-A | Labeled inhibitors of Prostate Specific Membrane Antigen (PSMA), their use as imaging agents and agents for treating prostate cancer | DEUTSCHES KREBSFORSCH | 2016-06-01 | — | — | CN | disclosed |
| WO-1999032887-A1 | DETECTION OF PROSTATE DISEASE BY MEASURING NAALADASE ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0660707-A4 | METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE. | CHILDRENS MEDICAL CENTER (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0660707-A1 | METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE | The Children's Medical Center Corporation (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994005275-A1 | METHOD OF PREVENTING NMDA RECEPTOR-MEDIATED NEURONAL DAMAGE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |